跳至主要内容
临床试验/NL-OMON43053
NL-OMON43053已完成4 期

Preventing contrAst induced Nephropathy after TranscathEter aortic valve Replacement - PANTER

Sint Antonius Ziekenhuis0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Patient has provided written informed consent.
  • 2. Patient is undergoing TAVI.
  • 3. Patient has an estimated GFR <60ml/min/1.73m2.

排除标准

  • 1. Patient has end-stage kidney disease requiring dialysis.
  • 2. Emergent TAVI (planned before next working day).
  • 3. Recent exposure to radiographic contrast agents (within 2 days prior to the TAVI).
  • 4. Allergy to contrast agent.
  • 5. Planned administration of dopamine, mannitol, fenoldopam or N-acetylcysteine during the intended time of the study.
  • 6. Need for continuous hydration therapy (e.g. sepsis).
  • 7. Multiple myeloma.
  • 8. Contra-indication to sodium bicarbonate.

研究者

相似试验